Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Treatment-Resistant Depression Market Size Changed, over the years?

The market size for treatment-resistant depression has seen robust growth recently. A rise from $1.76 billion in 2024 to $1.88 billion in 2025 with a compound annual growth rate (CAGR) of 7.1% is expected. The notable growth during the historic period is a result of increased cases of treatment-resistant depression, escalating instances of depression, enhanced access to health care services, heightened awareness about potential treatment methods, and a high incidence of mental health disorders.

How Much Will the Treatment-Resistant Depression Market Be Worth in 2029?

The market for treatment-resistant depression is set to witness significant expansion in the impending years, with a projection to reach $2.46 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this growth during the forecast period include a surge in chronic diseases, rising incidences of anxiety disorders, burgeoning awareness about mental well-being, government-led initiatives, and escalated healthcare spending. The forecast period is also expected to see trends like the rise of telemedicine and digital health, advancements in diagnostics and therapy technologies, initiatives to reduce mental health stigma, the acceptance of individualized medicine, and the implementation of artificial intelligence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23546&type=smp

Which is the Largest Company in the Treatment-Resistant Depression Market?

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, GlaxoSmithKline (GSK) plc., Hikma Pharmaceuticals plc, Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, Lykos Therapeutics, Reviva Pharmaceuticals, Celon Pharma SA, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience

What Are the Main Market Drivers in the Treatment-Resistant Depression Industry?

The high incidence of mental disorders is predicted to drive the expansion of the market for treatment-resistant depression. Mental disorders encompass a vast array of issues that impact an individual’s cognitive, emotional, and behavioural functions, frequently resulting in substantial distress and disruption to everyday routines. The high occurrence of mental disorders is triggered by elements like genetic predisposition, as inherited genetic differences can alter brain chemistry and enhance vulnerability to ailments such as depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) assists patients with mental disorders by promoting the application of more personalized and sophisticated treatments when standard therapies fail, thus improving their prospects of recovery and quality of living. For instance, in November 2023, the American Psychological Association (APA), a US-based scientific and professional institution, stated that adults aged 18 to 34 reported the highest instance of mental illnesses at 50% in 2023, while those aged 35 to 44 saw the greatest rise in diagnoses, with 45% reporting a mental illness. Consequently, the high incidence of mental disorders is propelling the expansion of the treatment-resistant depression market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23546&type=smp

How Is the Treatment-Resistant Depression Market Segments Structured?

The treatment-resistant depression market covered in this report is segmented –

1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS), Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Psychedelics, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram

2) Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline

3) Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline, Imipramine, Clomipramine, Doxepin

4) Psychedelics: Ketamine, Esketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), Other Drug Classes

5) Atypical Antipsychotics: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs), Glutamate Modulators, Hormonal Therapies

What Strategic Trends Are Transforming the Treatment-Resistant Depression Market?

Leading businesses in the treatment-resistant depression market are honing in on the creation of novel therapies such as monotherapy with the aim to fill gaps in patient treatment, enhance effectiveness and mitigate side effects. Monotherapy, which entails using a singular treatment or medication against a condition instead of multiple ones, addresses episodes of treatment-resistant depression by providing a single, concentrated treatment that might prove to be more effective for patients unresponsive to several medications. For example, Johnson & Johnson Services Inc., an American pharmaceutical, biotechnology, and medical technology corporation, made an announcement in January 2025 about obtaining approval from the U.S. Food and Drug Administration (FDA), a government regulatory body in the United States, for SPRAVATO (esketamine) nasal spray, an expedited treatment for adults suffering from treatment-resistant depression (TRD). SPRAVATO is administered in conjunction with an oral antidepressant when patients have demonstrated inadequate response to at least two other antidepressant therapeutics. The swift action of the drug addresses the inherent shortcomings of conventional antidepressants that usually take a few weeks to manifest effects. As a derivative of ketamine, esketamine operates by targeting the NMDA receptors in the brain, potentially lifting mood within a few hours. The ratification denoted a considerable leap forward in the realm of mental health treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/treatment-resistant-depression-global-market-report

Which Global Regions Offer the Highest Growth in the Treatment-Resistant Depression Market?

North America was the largest region in the treatment-resistant depression market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23546

This Report Delivers Insight On:

1. How big is the treatment-resistant depression market, and how is it changing globally?

2. Who are the major companies in the treatment-resistant depression market, and how are they performing?

3. What are the key opportunities and risks in the treatment-resistant depression market right now?

4. Which products or customer segments are growing the most in the treatment-resistant depression market?

5. What factors are helping or slowing down the growth of the treatment-resistant depression market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model